184 related articles for article (PubMed ID: 8622638)
61. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.
Baba M; De Clercq E; Tanaka H; Ubasawa M; Takashima H; Sekiya K; Nitta I; Umezu K; Walker RT; Mori S
Mol Pharmacol; 1991 Jun; 39(6):805-10. PubMed ID: 1711148
[TBL] [Abstract][Full Text] [Related]
62. Sensitivity of (138 Glu-->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors.
Balzarini J; Kleim JP; Riess G; Camarasa MJ; De Clercq E; Karlsson A
Biochem Biophys Res Commun; 1994 Jun; 201(3):1305-12. PubMed ID: 7517668
[TBL] [Abstract][Full Text] [Related]
63. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine.
Smith RA; Remington KM; Preston BD; Schinazi RF; North TW
J Virol; 1998 Mar; 72(3):2335-40. PubMed ID: 9499094
[TBL] [Abstract][Full Text] [Related]
64. 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.
Balzarini J; Pérez-Pérez MJ; San-Félix A; Schols D; Perno CF; Vandamme AM; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1992 May; 89(10):4392-6. PubMed ID: 1374900
[TBL] [Abstract][Full Text] [Related]
65. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
Schinazi RF; Lloyd RM; Nguyen MH; Cannon DL; McMillan A; Ilksoy N; Chu CK; Liotta DC; Bazmi HZ; Mellors JW
Antimicrob Agents Chemother; 1993 Apr; 37(4):875-81. PubMed ID: 7684216
[TBL] [Abstract][Full Text] [Related]
66. The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma.
Gray NM; Marr CL; Penn CR; Cameron JM; Bethell RC
Biochem Pharmacol; 1995 Sep; 50(7):1043-51. PubMed ID: 7575660
[TBL] [Abstract][Full Text] [Related]
67. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.
Murry JP; Higgins J; Matthews TB; Huang VY; Van Rompay KK; Pedersen NC; North TW
J Virol; 2003 Jan; 77(2):1120-30. PubMed ID: 12502828
[TBL] [Abstract][Full Text] [Related]
68. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
[TBL] [Abstract][Full Text] [Related]
69. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
Mathez D; Schinazi RF; Liotta DC; Leibowitch J
Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
[TBL] [Abstract][Full Text] [Related]
70. In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants.
McCrackin Stevenson MA; McBroom DG
Am J Vet Res; 2001 Apr; 62(4):588-94. PubMed ID: 11327469
[TBL] [Abstract][Full Text] [Related]
71. Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.
Halvas EK; Svarovskaia ES; Freed EO; Pathak VK
J Virol; 2000 Jul; 74(14):6669-74. PubMed ID: 10864683
[TBL] [Abstract][Full Text] [Related]
72. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
Kleim JP; Rösner M; Winkler I; Paessens A; Kirsch R; Hsiou Y; Arnold E; Riess G
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):34-8. PubMed ID: 8552634
[TBL] [Abstract][Full Text] [Related]
73. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.
Severini A; Liu XY; Wilson JS; Tyrrell DL
Antimicrob Agents Chemother; 1995 Jul; 39(7):1430-5. PubMed ID: 7492080
[TBL] [Abstract][Full Text] [Related]
74. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
[TBL] [Abstract][Full Text] [Related]
75. A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.
Smith RA; Remington KM; Lloyd RM; Schinazi RF; North TW
J Virol; 1997 Mar; 71(3):2357-62. PubMed ID: 9032372
[TBL] [Abstract][Full Text] [Related]
76. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.
Boyer PL; Gao HQ; Clark PK; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2001 Jul; 75(14):6321-8. PubMed ID: 11413298
[TBL] [Abstract][Full Text] [Related]
77. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.
Piras G; Nakade K; Yuasa S; Baba M
AIDS; 1997 Mar; 11(4):469-75. PubMed ID: 9084794
[TBL] [Abstract][Full Text] [Related]
78. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Brennan TM; Taylor DL; Bridges CG; Leyda JP; Tyms AS
Antiviral Res; 1995 Mar; 26(2):173-87. PubMed ID: 7541619
[TBL] [Abstract][Full Text] [Related]
79. [Conformation of crystalline 3'-nitro-2',3'-dideoxythymidine and properties of its 5'-triphosphate as a terminator substrate of retroviral reverse transcriptase].
Kuznetsova EV; Kukhanova MK; Gurskaia GV; Fedorov II; Ias'ko MV; Chattopadiiyaya J; Kraevskiĭ AA
Mol Biol (Mosk); 1995; 29(2):407-14. PubMed ID: 7540254
[TBL] [Abstract][Full Text] [Related]
80. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.
Quan Y; Brenner BG; Oliveira M; Wainberg MA
Antimicrob Agents Chemother; 2003 Feb; 47(2):747-54. PubMed ID: 12543687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
